SLC28A2 Antibody

What is SLC28A2 and why is it a target of interest for antibody-based research?

SLC28A2 (Solute Carrier Family 28 Member 2), also known as CNT2 (Concentrative Nucleoside Transporter 2), is a sodium-coupled nucleoside transporter that preferentially translocates purine nucleosides across the plasma membrane. It belongs to the CNTs family, which are Na+-nucleoside cotransporters with 14 predicted transmembrane domains (TMDs), featuring an intracellular N-terminus and an extracellular C-terminus .

The protein is of significant research interest because:

• It mediates the first step of nucleotide biosynthesis

• It participates in the absorption and disposition of endogenous nucleosides

• Its levels are highly dependent on insulin (but not glucose) concentration

• It plays a role in energy metabolism through ATP-sensitive K+ channels

• It modulates the cellular entry of anticancer and antiviral nucleoside analogs

Research into SLC28A2 has implications for understanding basic cellular physiology, drug transport mechanisms, and potential therapeutic targets in conditions involving nucleoside metabolism.

What are the standard applications for SLC28A2 antibodies in research?

SLC28A2 antibodies are utilized across multiple research applications with varying dilution requirements:

Different antibodies may show variable performance across these applications, so researchers should consult validation data for their specific antibody of interest .

What positive control samples are recommended for validating SLC28A2 antibodies?

Based on validation studies reported in the literature, the following samples have been successfully used as positive controls for SLC28A2 antibody testing:

When selecting positive controls, consider using tissues known to express the transporter physiologically, such as liver, kidney, and intestinal epithelia, where nucleoside transport is functionally important .

How can researchers address discrepancies between SLC28A2 transcript and protein levels in experimental results?

Discrepancies between mRNA and protein levels of SLC28A2 have been observed in research settings, as noted in a study examining gene expression in pulmonary hypertension models . This phenomenon can be addressed through several methodological approaches:

• Temporal analysis: Examine both transcript and protein levels across multiple time points, as post-transcriptional regulation may introduce a time lag between mRNA expression and protein accumulation.

• Post-translational modification assessment: As observed with TGFβ3 in the same study, "TGFβ3 protein levels were significantly higher in hypoxia/SU-5416 [than suggested by transcript levels]. This paradox may be explained by a number of regulatory mechanisms that contribute to greater TGFβ3 protein stability (steady-state levels) such as posttranslational modifications, sequestrations, and ubiquitinations compared with the turnover rate of the transcript."

• Comprehensive validation approach:

  • Use multiple antibodies targeting different epitopes

  • Employ transcript-specific methods (RT-PCR) alongside protein detection (Western blot, IHC)

  • Include knockout/knockdown controls when possible

  • Consider using absolute quantification methods for both transcript and protein

• Investigation of regulatory mechanisms: Explore whether microRNAs, RNA-binding proteins, or other post-transcriptional regulators may be affecting SLC28A2 expression in your experimental system.

Such discrepancies should be reported rather than ignored, as they may reveal important biological regulatory mechanisms relevant to nucleoside transport function.

What specialized techniques can be used to study SLC28A2 protein interactions and their functional implications?

Understanding SLC28A2 interactions with other proteins or cellular components requires specialized techniques beyond standard antibody applications:

Co-immunoprecipitation (Co-IP) Strategy

• Use anti-SLC28A2 antibodies (such as ABIN7186363 or ANT-062 ) that have been validated for IP

• Include appropriate membrane solubilization using non-denaturing detergents (critical for membrane proteins)

• Verify interactions with ATP-sensitive K+ channels, which have functional relationships with SLC28A2

Proximity Ligation Assay (PLA)

This technique can visualize protein-protein interactions in situ with high sensitivity:

• Use two primary antibodies (anti-SLC28A2 and antibody against suspected interaction partner)

• Follow with species-specific secondary antibodies linked to DNA oligonucleotides

• When proteins are in close proximity (<40 nm), DNA ligation and amplification generate fluorescent signals

Advanced Imaging for Transport Studies

Combining antibody-based detection with functional transport assays:

• Immunofluorescence to localize SLC28A2 (using antibodies like PA5-90922 )

• Simultaneous monitoring of nucleoside transport using fluorescently labeled nucleoside analogs

• Time-lapse imaging to correlate SLC28A2 localization with transport activity

These approaches provide deeper insights into the functional significance of SLC28A2 in nucleoside transport mechanisms and its regulation by other cellular components .

What are the critical parameters for optimizing Western blot protocols with SLC28A2 antibodies?

SLC28A2 is a multi-pass membrane protein with a calculated molecular weight of approximately 71 kDa, though observed weights may vary due to post-translational modifications . For optimal Western blot results:

Sample Preparation

• Membrane fraction enrichment: As a transmembrane protein, SLC28A2 detection may benefit from membrane fraction preparation rather than whole cell lysates

• Denaturation temperature: Use moderate heating (37-70°C) rather than boiling to prevent membrane protein aggregation

• Buffer selection: Include protease inhibitors and phosphatase inhibitors if phosphorylation status is relevant

Electrophoresis and Transfer

• Expected molecular weight: While calculated at ~71 kDa, the observed molecular weight may be 39 kDa for some antibodies due to processing or detection of specific fragments

• Transfer conditions: Use wet transfer methods with low SDS concentration for efficient transfer of membrane proteins

• Membrane selection: PVDF membranes are generally preferred for membrane proteins

Antibody Incubation

Include appropriate positive controls such as mouse liver or rat heart tissue lysates, which have been successfully used in validation studies .

What are the key considerations for immunohistochemical detection of SLC28A2 in tissue sections?

Successful immunohistochemical detection of SLC28A2 requires attention to several critical parameters:

Tissue Preparation and Antigen Retrieval

• Fixation: 10% neutral buffered formalin is commonly used, but fixation time should be optimized (excessive fixation may mask epitopes)

• Antigen retrieval: Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) is recommended for most SLC28A2 antibodies

• Section thickness: 4-5 μm sections are typically optimal for IHC applications

Staining Protocol Optimization

• Blocking: Use 5-10% normal serum from the same species as the secondary antibody

• Primary antibody dilution: Start with manufacturer recommendations (e.g., 1:50-1:100 for SAB4503566 , 1:100-1:300 for ABIN7186363 )

• Incubation conditions: Overnight incubation at 4°C may yield better results than shorter incubations at room temperature

• Detection system: Polymer-based detection systems often provide better sensitivity than traditional ABC methods

Controls and Interpretation

• Positive control tissues: Include human lung carcinoma (validated with antibody A36819 ) or liver sections

• Negative controls: Include (i) primary antibody omission, (ii) isotype controls, and (iii) when available, tissues known to be negative for SLC28A2

• Expected staining pattern: Primarily membrane localization with potential cytoplasmic signal

For quantification, intensity optical density (IOD) can be used, calculated as "the intensity of stain multiplied by the brown area in micrometers," similar to methods used in related studies .

How can SLC28A2 antibodies be used to investigate nucleoside transport in cancer research?

SLC28A2 plays critical roles in nucleoside metabolism relevant to cancer biology and therapeutics:

Investigating Drug Resistance Mechanisms

• Use anti-SLC28A2 antibodies (e.g., PA5-101897 ) to assess expression levels in sensitive versus resistant cell lines

• Correlate SLC28A2 protein levels with nucleoside analog drug efficacy

• Compare expression with other nucleoside transporters (ENTs, CNT1, CNT3) to understand comprehensive transport profiles

Tissue Expression Profiling

• Apply validated antibodies for IHC analysis of tumor microarrays (e.g., SAB4503566 or A36819 )

• Quantify expression differences between:

  • Tumor versus adjacent normal tissue

  • Primary tumors versus metastases

  • Different grades and stages of cancer progression

Functional Studies Integration

Combining antibody-based detection with nucleoside transport assays provides mechanistic insights:

• Assess correlation between SLC28A2 protein levels and transport rates of relevant nucleoside analogs

• Develop predictive biomarkers for nucleoside analog therapy response

• Investigate the potential of SLC28A2 as a therapeutic target itself

Such studies contribute to understanding how altered nucleoside transport affects cancer biology and response to nucleoside-based therapies.

What approaches can address the challenge of detecting orthologous SLC28A2 proteins across different species?

Cross-species detection of SLC28A2 requires careful antibody selection due to sequence variations between orthologs:

Sequence Homology Analysis

Epitope-Based Selection Strategy

• Conserved region targeting: Select antibodies raised against highly conserved regions between species

• Multiple antibody approach: Use species-specific antibodies when studying multiple species

• Validation requirements: Confirm cross-reactivity experimentally rather than relying solely on manufacturer claims

Cross-Species Experimental Design

When comparing SLC28A2 across species:

• Use antibodies specifically validated for each species of interest (e.g., ANT-062 validated for mouse and rat )

• Include appropriate positive controls from each species

• Consider using recombinant proteins as standards for quantitative comparisons

• Adjust detection conditions (antibody concentration, incubation time) for optimal signal in each species

This approach facilitates comparative studies of nucleoside transport mechanisms across model organisms while ensuring reliable detection .

How can researchers investigate potential relationships between SLC28A2 and metabolic pathways involving ATP-sensitive K+ channels?

The functional connection between SLC28A2 and ATP-sensitive K+ channels offers interesting research opportunities:

Co-localization Studies

• Use double immunofluorescence with anti-SLC28A2 antibodies (e.g., PA5-90922 ) and antibodies against K+ channel components

• Analyze subcellular distribution in tissues where both systems are physiologically relevant (pancreatic β-cells, cardiomyocytes)

• Quantify co-localization using Pearson's or Mander's coefficients

Functional Coupling Experiments

• Manipulate K+ channel activity pharmacologically while monitoring SLC28A2 expression and localization

• Assess whether insulin regulation of SLC28A2 involves K+ channel-dependent pathways

• Investigate metabolic stress conditions (hypoxia, nutrient deprivation) on the relationship between these systems

Molecular Interaction Analysis

• Use proximity ligation assays to visualize potential interactions in situ

• Employ co-immunoprecipitation with SLC28A2 antibodies validated for IP applications

• Investigate whether these interactions are altered in disease states or metabolic conditions

This research direction can provide insights into how nucleoside transport and energy metabolism are coordinated at the cellular level, with implications for understanding metabolic diseases and developing therapeutic approaches .

What are common problems encountered with SLC28A2 antibodies and how can they be addressed?

Researchers working with SLC28A2 antibodies may encounter several challenges:

Multiple Bands in Western Blot

Possible causes and solutions:

• Post-translational modifications: Compare observed bands with predicted modifications

• Protein degradation: Use fresh samples and include protease inhibitors

• Non-specific binding: Increase blocking time/concentration and optimize antibody dilution

• Splice variants: Verify which isoforms your antibody should detect based on the epitope location

Weak or No Signal

Possible causes and solutions:

• Low target expression: Use positive controls with known expression (HepG2, mouse liver )

• Antibody sensitivity: Try a more sensitive detection method or different antibody

• Epitope masking: Test alternative antigen retrieval methods (for IHC) or sample preparation protocols

• Storage issues: Ensure antibodies are stored properly (-20°C, avoid repeated freeze-thaw cycles )

Background or Non-specific Staining

Possible causes and solutions:

• Insufficient blocking: Increase blocking time or try alternative blocking reagents

• Antibody concentration: Titrate antibody to find optimal concentration

• Secondary antibody issues: Include secondary-only controls

• Cross-reactivity: Use antibodies with validated specificity (consider using blocking peptides like BLP-NT062 )

These troubleshooting strategies should be documented systematically to improve reproducibility and reliability of SLC28A2 detection across different experimental systems.

What validation standards should researchers apply when working with SLC28A2 antibodies?

Rigorous validation is essential for generating reliable data with SLC28A2 antibodies:

Recommended Validation Approach

• Specificity verification:

  • Test multiple antibodies targeting different epitopes

  • Include blocking peptide controls when available (e.g., SLC28A2/CNT2 Blocking Peptide BLP-NT062 )

  • Compare with genetic knockdown/knockout controls when possible

• Application-specific validation:

  • For each application (WB, IHC, ICC), perform separate optimization

  • Document optimal conditions including antibody dilution, incubation time, and buffer composition

  • Include multiple positive and negative controls

• Cross-reactivity assessment:

  • Verify species reactivity experimentally

  • Test in tissues with varying levels of target expression

  • Consider potential cross-reactivity with related transporters (CNT1, CNT3)

• Reproducibility testing:

  • Repeat experiments with different antibody lots when possible

  • Document batch variation

  • Consider using standardized positive controls across experiments

Boster Bio's validation approach illustrates good practice: "Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations."

How are SLC28A2 antibodies being used to investigate gene expression heterogeneity in single-cell studies?

Recent advances in single-cell analysis have revealed important insights about cellular heterogeneity in gene expression programs. For SLC28A2 research:

Single-Cell Protein Detection Methods

• Mass cytometry (CyTOF) with metal-conjugated SLC28A2 antibodies allows quantitative measurement across thousands of individual cells

• Single-cell Western blotting enables detection of protein expression heterogeneity in small cell populations

• Imaging mass cytometry combines antibody detection with spatial information in tissue sections

Correlating with Transcriptomic Data

Research has shown that gene expression at the transcript level can exhibit orthogonal patterns in co-stimulated macrophages . Similar approaches can be applied to SLC28A2:

• Compare protein-level heterogeneity (using antibodies) with transcript-level variation (from scRNA-seq)

• Investigate whether "cells with high levels of [one transcript] had no or very low expression of [another]"

• Calculate odds ratios between SLC28A2 and other transporters or related proteins to quantify expression relationships

Methodological Considerations

• Use highly specific antibodies with low background for reliable single-cell detection

• Include appropriate controls to distinguish true heterogeneity from technical variation

• Consider fixation and permeabilization conditions that preserve epitope accessibility

This frontier of research provides opportunities to understand how nucleoside transport capacity varies among seemingly identical cells within a tissue or culture system.

What emerging applications exist for SLC28A2 antibodies in studying disease mechanisms beyond cancer?

While cancer research has been a primary focus for nucleoside transporter studies, SLC28A2 antibodies are increasingly utilized in other disease contexts:

Pulmonary Hypertension Research

Studies have identified SLC28A2 as "especially unique (identified in 3 of the 5 total studies)" comparing gene expression in pulmonary hypertension models . Antibody-based detection can:

• Validate transcriptome findings at the protein level

• Localize expression changes to specific cell types within the lung

• Track response to therapeutic interventions

Metabolic Disorders

Given the relationship between SLC28A2 and insulin signaling , antibody applications include:

• Investigating SLC28A2 expression changes in diabetes models

• Correlating transporter levels with insulin resistance markers

• Exploring potential as a biomarker for metabolic syndrome

Neurodegenerative Diseases

Nucleoside metabolism has implications for neurological conditions:

• Mapping SLC28A2 distribution in normal versus diseased brain tissue

• Investigating changes during disease progression

• Assessing potential as a therapeutic target for conditions involving purinergic signaling disruption

These emerging applications demonstrate the versatility of SLC28A2 antibodies beyond their traditional use in cancer and basic transport studies, opening new avenues for understanding disease mechanisms.